中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

重组人血管内皮抑制素联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响

郝明志 林海澜 陈起忠 胡育斌

郝明志, 林海澜, 陈起忠, 胡育斌. 重组人血管内皮抑制素联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响[J]. 临床肝胆病杂志, 2016, 32(1): 92-96. DOI: 10.3969/j.issn.1001-5256.2016.01.016
引用本文: 郝明志, 林海澜, 陈起忠, 胡育斌. 重组人血管内皮抑制素联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响[J]. 临床肝胆病杂志, 2016, 32(1): 92-96. DOI: 10.3969/j.issn.1001-5256.2016.01.016
Hao MingZhi, Lin HaiLan, Chen QiZhong, Hu YuBin. Effect of recombinant human endostatin combined with hepatic artery interventional therapy on progression-free survival of patients with advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2016, 32(1): 92-96. DOI: 10.3969/j.issn.1001-5256.2016.01.016
Citation: Hao MingZhi, Lin HaiLan, Chen QiZhong, Hu YuBin. Effect of recombinant human endostatin combined with hepatic artery interventional therapy on progression-free survival of patients with advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2016, 32(1): 92-96. DOI: 10.3969/j.issn.1001-5256.2016.01.016

重组人血管内皮抑制素联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响

DOI: 10.3969/j.issn.1001-5256.2016.01.016
详细信息
  • 中图分类号: R735.7

Effect of recombinant human endostatin combined with hepatic artery interventional therapy on progression-free survival of patients with advanced hepatocellular carcinoma

  • 摘要:

    目的观察重组人血管内皮抑制素(恩度)联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响。方法选取2011年3月-2015年5月福建省肿瘤医院收治的86例中晚期肝癌患者,按照配对设计分为治疗组和对照组。治疗组(n=43)采用恩度联合肝动脉介入治疗;对照组(n=43)采用肝动脉介入治疗联合口服中药肝复乐。计数资料组间比较采用χ2检验,计量资料组间比较采用t检验。Kaplan-Meier法进行生存分析,单因素分析采用Log-rank法,多因素回归分析采用Cox比例风险模型。结果治疗组和对照组的中位无疾病进展生存期分别为154 d[95%可信区间(95%CI):94214 d]、70 d(95%CI:39101 d),两组比较差异具有统计学意义(χ2=10.741,P=0.001)。单因素分析显示,肝硬化严重程度、肿瘤个数、门静脉主干癌栓/下腔静脉癌栓是中晚期肝癌患者预后的影响因素(χ2值分别为8.182、9.150、6.565,P值分别为0.004、0.027、0.038);多因素分析显示,肝硬化严重程度、门静脉主干癌栓/下腔静脉癌栓是恩度联合肝...

     

  • [1]YE SL,QIN SK,WU MC,et al.Consensus on standardized diagnosis and treatment of primary liver cancer[J].J Clin Hepatol,2009,25(2):83-92.(in Chinese)叶胜龙,秦叔逵,吴孟超,等.原发性肝癌规范化诊治的专家共识[J].临床肝胆病杂志,2009,25(2):83-92.
    [2]DIGTYAR AV,POZDNYAKOVA NV,FELDMAN NB,et al.Endostatin:current concepts about its biological role and mechanisms of action[J].Biochemistry(Mosc),2007,72(3):235-246.
    [3]HUANG X,WONG MK,ZHAO Q,et al.Soluble recombinant endostatin purified from Escherichia coli:antiangiogenic activity and antitumor effect[J].Cancer Res,2001,61(2):478-481.
    [4]LI B,WU XY,ZHOU H,et al.Acid-induced unfolding mechanism of recombinant human endostatin[J].Biochemistry,2004,43(9):2550-2557.
    [5]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
    [6] HAO MZ,LIN HL,CHEN QZ,et al.Efficacy of transcatheter arterial infusion alone or combined with transcatheter arterial chemoembolization on advanced hepatocellular carcinoma with portal vein tumor thrombus in the main trunk[J/OL].Contemp Interv Med,2015,1(3).http://www.intervmed.com/2015010316.html.(in Chinese)郝明志,林海澜,陈起忠,等.合并门脉主干癌栓的晚期肝癌肝动脉介入治疗的疗效观察[J/OL].当代介入医学,2015,1(3).http://www.intervmed.com/2015010316.html.
    [7]LENCIONI R,LLOVET JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60.
    [8]WEI Y,TU R,CHEN ZM,et al.Hepatic functional reserve and prognosis after liver interventional therapy:evaluation by CT grading of liver cirrhosis[J].J Clin Radiol,2010,29(12):1671-1674.(in Chinese)韦勇,涂蓉,陈忠明,等.肝硬化CT分级评估肝癌介入治疗肝储备功能及预后研究[J].临床放射学杂志,2010,29(12):1671-1674.
    [9]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.
    [10]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.
    [11]MARUYAMA K,OCHIAI A,AKIMOTO S,et al.Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer[J].Oncology,2000,59(4):302-309.
    [12]ANDO E,TANAKA M,YAMASHITA F,et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases[J].Cancer,2002,95(3):588-595.
    [13]KUDO M,MATSUI O,IZUMI N,et al.JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma:2014 update by the liver cancer study group of Japan[J].Liver Cancer,2014,3(3-4):458-468.
    [14]FOLKMAN J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Exp Cell Res,2006,312(5):594-607.
    [15]WANG JW,SUN Y,LIU YY,et al.Results of randomized,multicenter,double-blind phaseⅢtrial of rh-endostatin(YH-16)in treatment of advanced non-small cell lung cancer patients[J].Chin J Lung Cancer,2005,8(4):283-290.(in Chinese)王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290.
    [16]LIU XF,QIN SK,WANG L,et al.Endostar combined with chemotherapy on the multiple kinds of advanced malignancies[J].Chin Clin Oncol,2007,12(4):241-245.(in Chinese)刘秀峰,秦叔逵,王琳,等.恩度与化疗联合治疗多种晚期恶性肿瘤的临床观察[J].临床肿瘤学杂志,2007,12(4):241-245.
    [17]REN TJ,SHAN FX,HOU JF,et al.Efficacy and safety of combined XELOX and Endostar therapy as first-line treatment for patients with advanced biliary tract carcinoma[J].Chin J Oncol Prev Treat,2015,7(1):41-44.(in Chinese)任铁军,单风晓,侯建峰,等.XELOX方案联合恩度一线治疗晚期胆系肿瘤的临床观察[J].中国癌症防治杂志,2015,7(1):41-44.
    [18]WANG YZ.Endostar infusion combined with interventional chemotherapy and embolization interventional therapy in treatment of advanced liver cancer[J].Modern Prevent Med,2011,38(2):399-341.(in Chinese)王永中.恩度静脉滴注联合介入化疗栓塞治疗中晚期肝癌的临床研究[J].现代预防医学,2011,38(2):399-341.
    [19]HAO MZ,CHEN WJ,LIN HL,et al.Efficacy of transcatheter arterial chemoembolization combined with Ganfule capsules on advanced hepatocellular carcinoma[J].Central South Pharm,2013,11(2):147-150.(in Chinese)郝明志,陈武进,林海澜,等.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].中南药学,2013,11(2):147-150.
    [20]JEONG SW,JANG JY,SHIM KY,et al.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J].Gut Liver,2013,7(6):696-703.
    [21]ZHANG Y,FAN W,WANG Y,et al.Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis:a retrospective analysis[J].Oncologist,2015,20(12):1417-1424.
    [22]MENG ZQ,LIU LM,MA X,et al.Prognosis risk factors and therapeutic effect analysis in primary hepatic carcinoma:394 cases report[J].China Oncol,2007,17(8):628-632.(in Chinese)孟志强,刘鲁明,马鑫,等.394例原发性肝癌的预后因素与疗效分析[J].中国癌症杂志,2007,17(8):628-632.
    [23]JIA QL,GAO WQ.Prognostic factors affecting TACE treatment in patients with primary hepatic carcinoma[J].J Henan Univ Sci Tech:Med Sci,2009,27(2):158-160.(in Chinese)贾群玲,高万勤.影响原发性肝癌病人TACE治疗的预后因素[J].河南科技大学学报:医学版,2009,27(2):158-160.
  • 加载中
计量
  • 文章访问数:  2230
  • HTML全文浏览量:  3
  • PDF下载量:  408
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-10-19
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回